Status:
TERMINATED
Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)
Lead Sponsor:
Aura Biosciences
Conditions:
Choroidal Melanoma
Indeterminate Lesions
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective multicenter, group-matched study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with belzupacap sarotalocan (bel-sar; AU-011) and pati...
Detailed Description
Up to approximately 45 patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the Investigator are planned to be enrolled.
Eligibility Criteria
Inclusion
- Have per the investigator's expert clinical judgment, a clinical diagnosis of primary indeterminate lesion or choroidal melanoma based on the clinical history, ophthalmic examination, fundus photography and conventional ocular ultrasound.
Exclusion
Key Trial Info
Start Date :
April 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 20 2023
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT05266430
Start Date
April 14 2022
End Date
April 20 2023
Last Update
August 9 2023
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Associated Retinal Consultants, P.C.
Royal Oak, Michigan, United States, 48073
2
Oregon Health & Science University Casey Eye Institute
Portland, Oregon, United States, 97239
3
Retina Consultants of Carolina, PA
Greenville, South Carolina, United States, 29605
4
St. Thomas Health/Tennessee Retina, P.C.
Nashville, Tennessee, United States, 37203